News

Pfizer (NYSE: PFE) celebrates its 175th anniversary this year, so the pharma giant has a long history. But the drugmaker actually jumped into the global spotlight not long ago when it launched its

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q4 2023 Earnings CallJan 31, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Good news from the lab sparked a mini-rally in Vertex Pharmaceuticals (NASDAQ: VRTX) stock on Tuesday. The biotech's shares closed the trading session more than 2% higher in price, which was good

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q4 2023 Earnings CallJan 30, 2024, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Pfizer (NYSE: PFE) jumped as much as 3.2% higher on Tuesday morning before giving up all of the gains and then some. The pharma stock was down by 0.6% as of 12:05 p.m. ET.

These gyrations

As dividend investors know, there's an upside to investing in a big pharmaceutical business like Amgen (NASDAQ: AMGN) for dividend income. It likely has the resources and proven capabilities that'll

Famed investor Warren Buffett once said he aimed to be greedy when others were fearful. Here's one way to apply this bit of advice when investing in stocks: Equities that look beaten-down can be

Microsoft, Apple, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla -- a group that Bank of America analyst Michael Hartnett dubbed the "Magnificent Seven," -- have taken the market by storm for

With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over

Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.

UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) are two of the largest healthcare companies in the world. One is focused on health insurance, while the other makes medical devices

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Time in the market beats timing the market, hands-down. But how long should you own a stock?

Famed investor Warren Buffett perhaps said it best: "When we own portions of outstanding businesses with

Shares of Humana (NYSE: HUM) are down 11.7% on Thursday after the health insurance giant announced weaker-than-expected quarterly results and light profit guidance for the coming year.

Humana's

Shares of ResMed (NYSE: RMD) were jumping 7% as of 11:25 a.m. ET on Thursday after rising as much as 10.6% earlier in the morning. The solid gain came after the medical device maker announced

Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.

However, a lot has changed for

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for

Building a balanced portfolio requires careful planning and execution. You need to think about your long-term objectives for growth and income, as well as tax implications, when you need to adjust

As you build your portfolio through the years, you may find that you gravitate toward stocks across an assortment of sectors, with a range of risk profiles, growth stories, and businesses

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set